Community-acquired Clostridium difficile NAP1/027-associated diarrhea in an eighteen month old child

Carlos Quesada-Gómez1, Pablo Vargas, Diana López-Ureña

  • 1Laboratorio de Investigación en Bacteriología Anaerobia (LIBA), Facultad de Microbiología and Centro de Investigación en Enfermedades Tropicales, Universidad de Costa Rica, 2060 Montes de Oca, San Jose, Costa Rica.

Anaerobe
|November 3, 2012
PubMed

Insights

Clostridium difficile infection (CDI) can cause severe diarrhea, especially after antibiotic use. This report details the first documented case of community-acquired CDI caused by a hypervirulent strain in a young child in Latin America.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pediatrics

Background:

  • Clostridium difficile infection (CDI) is a significant healthcare-associated complication, often linked to antibiotic therapy.
  • Emerging evidence indicates CDI is an increasingly recognized cause of pediatric diarrhea in both community and hospital environments.

Observation:

  • This study documents a rare case of community-acquired CDI in an eighteen-month-old child residing in Latin America.
  • The infection was attributed to a NAP1 hypervirulent strain, known for its increased pathogenicity.

Findings:

  • This case represents the first documented instance of community-acquired CDI caused by a NAP1 hypervirulent strain in a pediatric patient from Latin America.
  • The findings highlight the potential for hypervirulent strains to cause infections outside traditional healthcare settings in young children.

Implications:

  • This case underscores the importance of considering CDI in pediatric diarrhea, even in community settings, particularly with hypervirulent strains.
  • Further research is warranted to understand the epidemiology and risk factors for community-acquired CDI in children within Latin America and globally.

Related Concept Videos

Bacterial Gastroenteritis01:18

Bacterial Gastroenteritis

Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid receptor...
Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from the skin...
Development of the Oral Microbiota01:28

Development of the Oral Microbiota

The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Diphtheria01:28

Diphtheria

Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...